logo-loader
viewAmryt Pharma PLC

Amryt Pharma announces 'positive' results from rare skin disease trial

Amryt Pharma PLC's (NASDAQ:AMYT) (LON:AMYT) Joe Wiley talks to Proactive London's Katie Pilbeam after revealing 'positive results' from the phase III success of FILSUVEZ, a gel for a rare and extremely painful skin condition called epidermolysis bullosa (EB).

The results showed which products increased the speed of wound healing in the disease and if approved, this would be the first available treatment for EB.

Wiley explains the challenges of such a trial which involved 223 people, 156 of which were children to research a disease that impacts over 500,000 people worldwide.

Quick facts: Amryt Pharma PLC

Price: 206 GBX

AIM:AMYT
Market: AIM
Market Cap: £335.37 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Amryt Pharma PLC named herein, including the promotion by the Company of Amryt Pharma PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Market report: Sterling six week lows and further lockdown woes

The FTSE is higher as we head into early afternoon trade with Sterling still loitering around that six week low and news from drug giant AstraZeneca PLC (LON:AZN) that it is putting its coronavirus vaccine trials on hold after a patient participating got poorly which has triggered...

on 9/9/20

2 min read